Baebies Inc., Durham, NC, USA
www.baebies.com

FINDER Bacteremia
RAPID NEAR-PATIENT ID/AST 
Diagnostic for Neonatal Sepsis

Baebies is developing a novel small footprint diagnostic instrument for rapid diagnosis of neonatal sepsis. The system provides a two-fold diagnosis. First a rapid test of 15 minutes to determine if the infection is due to bacteria. This is followed by a post blood culture rapid 15-minute molecular test for pathogen identification and antibiotic sensitivity. The speed and sensitivity of these tests is underpinned by Baebies’ patented digital microfluidic technology. With a focus on small volumes and rapid testing, Baebies aims to meet an important medical need for neonates.

Current Development Stage: Feasibility

CARB-X Investment: Initial investment of up to $3.9m with potential option payments up to $7.7m.

Initial CARB-X Investment Date: February 1, 2021